[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596897":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":31,"locations":25,"responsibleParty":41,"collaborators":43,"id":47,"slug":25,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":25,"enrollmentInfo":56,"targetDuration":25,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":25,"overallStatus":65,"whyStopped":25,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":25},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Precision approach to K Prescription for HD (PKRxHD)","EXPERIMENTAL","Participants will receive a novel dialysate potassium (K) management strategy.",[13,14],"Other: PKRxHD","Procedure: Dialysis",{"label":16,"type":17,"description":18,"interventionNames":19},"Usual Care","ACTIVE_COMPARATOR","Standard dialysis potassium prescribing.",[14],[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PKRxHD","The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"PROCEDURE","Dialysis","Standard of care dialysis.",[9,16],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"David Charytan, MD","CONTACT","212-263-0705","David.Charytan@nyulangone.org",{"name":38,"role":34,"phone":39,"phoneExt":25,"email":40},"Zoe Rimler","212-263-2544","Zoe.Rimler@nyulangone.org",{"type":42,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[44],{"name":45,"class":46},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100596897",false,"NCT07051447","The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial","The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial (RADAR-K): A Randomized, Controlled, Pilot Trial Comparing Usual Care to a Precision Approach to Dialysis Potassium Prescribing.","RADAR-K","Inclusion Criteria:\n\n* Undergoing in-center, 3x\u002Fweekly HD for treatment of end-stage kidney disease (ESKD) for at least 90 days\n* Age at least 21 years\n* Prescribed HD time up to 15 hours\u002F week\n\nExclusion Criteria:\n\n* Incarcerated\n* Life expectancy of 1 year or less\n* Kidney transplant, transition to home dialysis, or transfer to non-participating HD unit anticipated within 6 months or less\n* Cognitive condition that precludes consent\n* Severe anemia (hemoglobin \\\u003C 8.0 g\u002FdL) within 30 days\n* K concentration of 7.0 mEq\u002FL or more within 60 days\n* Pregnant women\n* Women of childbearing potential actively trying to conceive unwilling to use contraception\n* Participation in other interventional studies within 30 days prior to enrollment","ALL","21 Years",{"count":57,"type":58},120,"ESTIMATED","INTERVENTIONAL",[61],"NA","This will be a randomized controlled pilot trial comparing usual care to a precision approach to dialysis potassium prescribing. The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).",[64],"End Stage Kidney Disease","NOT_YET_RECRUITING","2025-06-26",{"date":68,"type":69},"2025-07-04","ACTUAL",{"date":71,"type":58},"2025-08-01",{"date":73,"type":58},"2029-08-01",{"name":5,"class":6}]